Did AVITA Medical beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for AVITA Medical year over year?

What is AVITA Medical's latest dividend and current dividend yield?

What is AVITA Medical's gross profit margin?

What were the key takeaways from AVITA Medical's earnings call?

What factors drove the changes in AVITA Medical's revenue and profit?

What does AVITA Medical do and what are its main business segments?

What were the key takeaways from AVITA Medical’s earnings call?

- **Revenue Miss and Guidance Adjustment**: Q3 revenue $17.1M (-13% YoY), full-year revised to $70-74M due to reimbursement delays.
- **Reimbursement Resolution**: All MACs resolved provider rates, clearing path for RECELL demand recovery.
- **Commercial Restructuring**: 200 key U.S. accounts targeted for $1.3B opportunity; 24% cost reduction ($23M opex) driving cash flow improvement.
- **Global Expansion**: First European patient treated with RECELL GO; cautious European rollout while focusing on U.S. recovery.
- **Cash Position**: $23.3M cash, $6.2M Q3 cash use (vs. $10.1M Q2), with path to breakeven as revenue recovers.


**【CEO Summary Section】**
- **Q3 2025 Revenue**: $17.1 million, down 13% YoY, due to reimbursement delays and slower-than-expected VAC approvals. Full-year guidance revised to $70-74 million (prior: $76-81 million). 
- **Reimbursement Progress**: All 7 MACs have resolved provider reimbursement rates, clearing uncertainty for RECELL procedures. Early signs of demand recovery as clinicians regain confidence.
- **Market Focus**: 200 key U.S. burn/trauma centers represent $1.3 billion of the $3.5 billion TAM. Current penetration ~5%, with priority on scaling utilization in high-value accounts.
- **Commercial Restructuring**: Streamlined sales org, improved forecasting, and monthly purchasing patterns to drive predictability. 
- **Cost Discipline**: Operating expenses reduced 24% YoY ($23M vs. $30.2M), with $10M annualized savings. Balance sheet flexibility maintained via debt covenant amendments.
- **Global Expansion**: RECELL GO received CE Mark in Europe, with first patient treated in Germany. Limited resources allocated to early-stage European distribution.

**【CFO Financial Commentary】**
- **Gross Margin**: 81.3% (vs. 83.7% Q3 2024), impacted by Cohealyx/PermeaDerm mix (50%/60% ASP share). RECELL gross margin remains stable at 83.6%.
- **Cash Position**: $23.3 million at end of Q3, up from $15.7 million, driven by $13.8 million private placement and reduced cash burn ($6.2M vs. $10.1M Q2). 
- **Debt Management**: Secured Q3 revenue covenant waiver and Q4 amendment to $70 million. Evaluating 2026 capital strategy for cash flow breakeven.

**【Q&A Highlights】**
- **Forecasting**: Improved visibility via rep-level customer engagement and monthly purchasing patterns. 2026 guidance to be updated in Q1 2026.
- **Europe Strategy**: Limited resources for early-stage European launch, with focus on U.S. recovery. No bifurcation of resources expected.
- **VAC Approvals**: ~1/3 of target accounts have Cohealyx VAC submissions; expect ordering to begin post-approval. Synergies from full portfolio utilization in ~20 accounts, but early days.
- **Sales Incentives**: 2026 comp plans to align with growth objectives, emphasizing portfolio sales and utilization consistency.
- **Backlog Catch-Up**: No material impact on 2025 guidance from delayed claims adjudication; focus on 2026 recovery.


AVITA Medical, Inc. (RCEL) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

RCEL

RCEL fundamentals

You can ask Aime